Landscape Capital Management L.L.C. Makes New Investment in Palisade Bio, Inc. $PALI

Landscape Capital Management L.L.C. bought a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the second quarter, HoldingsChannel reports. The firm bought 436,726 shares of the company’s stock, valued at approximately $913,000.

Several other hedge funds have also modified their holdings of PALI. Perceptive Advisors LLC purchased a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $28,318,000. Commodore Capital LP purchased a new position in Palisade Bio in the fourth quarter worth $26,896,000. Janus Henderson Group PLC purchased a new position in Palisade Bio in the fourth quarter worth $24,822,000. BlackRock Inc. acquired a new stake in Palisade Bio in the second quarter valued at $21,813,000. Finally, RA Capital Management L.P. acquired a new stake in Palisade Bio in the fourth quarter valued at $16,742,000. 11.79% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Oppenheimer began coverage on shares of Palisade Bio in a research report on Thursday, July 23rd. They set an “outperform” rating and a $8.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a report on Tuesday, June 30th. LADENBURG THALM/SH SH upgraded shares of Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Finally, Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $9.00.

Insiders Place Their Bets

In other Palisade Bio news, insider Mitchell Lawrence Jones sold 51,880 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total value of $106,354.00. Following the sale, the insider owned 94,009 shares of the company’s stock, valued at $192,718.45. This represents a 35.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera purchased 30,000 shares of Palisade Bio stock in a transaction on Tuesday, July 7th. The stock was acquired at an average cost of $2.03 per share, for a total transaction of $60,900.00. Following the acquisition, the director directly owned 416,904 shares of the company’s stock, valued at approximately $846,315.12. This represents a 7.75% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 125,000 shares of company stock worth $250,100. Insiders own 0.07% of the company’s stock.

Palisade Bio Price Performance

Shares of PALI stock opened at $2.10 on Monday. Palisade Bio, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.86. The stock has a market cap of $365.97 million, a P/E ratio of -4.38 and a beta of 1.52. The business has a fifty day simple moving average of $1.99 and a 200-day simple moving average of $1.93.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.50 million. On average, sell-side analysts anticipate that Palisade Bio, Inc. will post -0.23 earnings per share for the current year.

Palisade Bio Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.